Table 1 Posted results of monotherapy with pembrolizumab, atezolizumab, nivolumab, durvalumab and avelumab in advanced NSCLC

NCT01295827

Keynote 001

Pembrolizumab

I

Second line

Advanced NSCLC

Pembrolizumab

Regardless PD-L1

19.40%

3.7 m

12.0 m

NR

9.50%

PD-L1 ≥ 50%

45.20%

6.3 m

NR

12.5 m

NA

NCT01905657

Keynote 010

Pembrolizumab

II/III

Second line

Previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells

Pembrolizumab = 2 mg/kg

PD-L1 ≥ 50%

30.00%

5.0 m

14.9 m

NR

13.00%

Pembrolizumab = 10 mg/kg

PD-L1 ≥ 50%

29.00%

5.2 m

17.3 m

NR

16.00%

Docetaxel

PD-L1 ≥ 50%

8.00%

4.1 m

8.9 m

8 m

35.00%

NCT02142738

Keynote 024

Pembrolizumab

III

First line

Previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no mutation of EGFR or ALK

Pembrolizumab 200 mg/3 weeks

PD-L1 ≥ 50%

44.80%

10.3 m

NR

NR

26.60%

Platinum-based chemotherapy

27.80%

6.0 m

14.5 m

6.3 m

53.30%

NCT02220894

Keynote 042

Pembrolizumab

III

First line

Previously untreated advanced non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with ECOG 0 or 1, and a PD-L1 TPS of 1% or greater

Pembrolizumab

PD-L1 ≥ 50%

39.50%

7.1 m

20.0 m

20.2 m

17.80%

PD-L1 ≥ 20%

33.40%

6.2 m

17.7 m

PD-L1 ≥ 1%

27.30%

5.4 m

16.7 m

Platinum-based chemotherapy

PD-L1 ≥ 50%

32.00%

6.4 m

12.1 m

10.8 m

41.90%

PD-L1 ≥ 20%

28.90%

6.6 m

13.0 m

8.3 m

PD-L1 ≥ 1%

26.50%

6.5 m

12.1 m

8.3 m

NCT02008227

OAK

Atezolizumab

III

Second line

Previously treated NSCLC

Atezolizumab

ITT population

14.00%

2.8 m

13.8 m

16.3 m

15.00%

Docetaxel

13.00%

4.0 m

9.6 m

6.2 m

43.00%

NCT01642004/NCT01673867

Checkmate 017/057

Nivolumab

III

Second line

Previously treated patients with advanced squamous or nonsquamous non–small-cell lung cancer

Nivolumab

NA

NA

2.56 m

11.1 m

Squamous: 25.2 m

10.00%

Non-squamous: 17.2 m

Docetaxel

NA

3.52 m

8.1 m

Squamous: 8.4 m

55.00%

Non-squamous: 5.6 m

NCT01693562

Study 1108

Durvalumab

I/II

Second line

Pretreated NSCLC EGFR/ALK wild type

Durvalumab from 0.1 to 10 mg/kg q2w or 15 mg/kg q3w

PD-L1 ≥ 25%

25.30%

2.8 m

15.4 m

NR

10.00%

PD-L1<25%

6.10%

1.5 m

7.6 m

First line

Treatmentnaïve advanced NSCLC EGFR/ALK wild type

Durvalumab

10 mg/kg q2w

PD-L1 ≥ 25%

28.60%

4.0 m

21 m

NR

9.00%

PD-L1<25%

11.00%

NA

NA

NCT02220894

ATLANTIC

Durvalumab

II

Third line

Heavily pretreated advanced NSCLC EGFR/ALK positive

Durvalumab

PD-L1 ≥ 25%

14.10%

1.9 m

13.3 m

7.4 m

5.40%

PD-L1<25%

3.60%

1.9 m

9.9 m

NR

Heavily pretreated advanced NSCLC EGFR/ALK wild type or unknown

Durvalumab

PD-L1 ≥ 90%

30.90%

2.4 m

NR

NR

17.60%

PD-L1 ≥ 25%

7.50%

3.3 m

10.9 m

8.20%

PD-L1<25%

3.30%

1.9 m

9.3 m

NCT02766335

Lung-Map

Durvalumab

II

Second line

Pretreated NSCLC EGFR/ALK wild type

Durvalumab

PD-L1 ≥ 25%

14.30%

NA

10.7 m

NR

34.00%

PD-L1<25%

6.90%

NA

11.6 m

Docetaxel

NA

6.70%

NA

7.7 m

NR

NA

NCT02125461

PACIFIC

Durvalumab

III

Second line

Unresectable stage III NSCLC after chemoradiation Regardless of PD-L1 status

Durvalumab

NA

28.40%

16.8 m

23.2 m

NR

29.90%

Placebo

16.00%

5.6 m

14.6 m

26.10%

NCT02395172

JAVELIN Lung 200

Avelumab

III

Second line

Platinum-treated patients with advanced NSCLC

Avelumab

PD-L1 ≥ 1%

19.00%

3.4 m

11.4 m

NR

10.00%